NF-kappaB p65 Ab

Cat.#: AF5006  
Size: 100ul, 200ul  
Concn.: 1mg/ml  
Source: Rabbit  
Mol.Wt.: 65kDa  
Clonality: Polyclonal


Reactivity: Human, Mouse, Rat, Monkey

Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

Specificity: NF-kappaB p65 Ab detects endogenous levels of total NF-kappaB p65.

Immunogen: A synthesized peptide derived from human NF-kappaB p65, corresponding to a region within C-terminal amino acids.

Uniprot: Q04206

Description: NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL (MIM 164910), RELA, or RELB (MIM 604758) to form the NFKB complex. The p50 (NFKB1)/p65 (RELA) heterodimer is the most abundant form of NFKB. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA, MIM 164008 or NFKBIB, MIM 604495), which inactivate NFKB by trapping it in the cytoplasm.

Subcellular Location: Nucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalized with RELA in the nucleus upon TNF-alpha induction.

Similarity: the 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.

Storage Condition and Buffer: Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Western blot analysis of NF-kappaB p65 using various lysates Lanes 1 - 2: Merged signal (red and green). Green - AF5006 observed at 65 kDa. Red - loading control, T0004, observed at 36 kDa. Blots were developed with Goat Anti-Rabbit IgG(H+L) FITC-conjugated (S0008) and Goat Anti-Mouse IgG(H+L) Alexa Fluor 594-conjugated (S0005) secondary antibodies.
Western blot analysis of extracts from various samples, using NF-kappaB p65 Ab.
Lane 1: Rat lung treated with blocking peptide;
Lane 2: Rat lung;
Lane 3: VERO.

Western blot analysis of extracts from various samples, using NF-kappaB p65 Ab.
Lane 1: Mouse brain treated with blocking peptide;
Lane 2: Mouse brain;
Lane 3: Hybridoma cells;
Lane 4: HeLa;
Lane 5: Vero.

Western blot analysis of extracts from various samples, using NF-kappaB p65 Ab.
Lane 1: hela treated with blocking peptide.
Lane 2: Hela;
Lane 3: Hepg2;

Western blot analysis of NF-kappaB p65 expression in Rat spleen lysate

AF5006 at 1/100 staining Human Breast Cancer tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the Ab for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit Ab was used as the secondary.

AF5006 staining HeLa by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100, then blocked in 10% serum for 45 minutes at 25°C. The primary Ab was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) Ab, diluted at 1/600, was used as the secondary Ab.
AF5006 staining lovo cells by ICC/IF. Cells were fixed with PFA and permeabilized in 0.1% saponin prior to blocking in 10% serum for 45 minutes at 37°C. The primary Ab was diluted 1/400 and incubated with the sample for 1 hour at 37°C. A Alexa Fluor® 594 conjugated goat polyclonal to rabbit IgG (H+L), diluted 1/600 was used as secondary Ab.

**IMPORTANT:** For western blot, incubate membrane with diluted primary Ab in 5% w/v milk, 1X TBS, 0.1% Tween®20 at 4°C with gentle shaking, overnight.